{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:33:31Z","timestamp":1791027211475,"version":"4.1.0"},"reference-count":55,"publisher":"Wiley","issue":"11P2","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4094,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2000,11]]},"abstract":"<jats:p>Numerous clinical trials have highlighted the role of the renin\u2010angiotensin\u2010aldosterone (RAA) system in the development and progression of heart failure. Over 30 randomized, controlled trials have evaluated the effects of angiotensin\u2010converting enzyme (ACE) inhibitors on morbidity and mortality in over 7000 patients with heart failure. Cumulative evidence from these trials shows that these agents significantly reduce mortality and hospitalizations, slow disease progression, and improve exercise tolerance and New York Heart Association class. The Heart Failure Society of America guidelines recommend ACE inhibitors as standard therapy for patients with left ventricular systolic dysfunction. The angiotensin receptor blockers and spironolactone offer alternative and perhaps complimentary mechanisms by which the RAA system may be therapeutically manipulated. The role of these therapies in treating heart failure is discussed.<\/jats:p>","DOI":"10.1592\/phco.20.18.368s.34606","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T10:37:27Z","timestamp":1086777447000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Role of the Renin\u2010Angiotensin\u2010Aldosterone System in the Management of Heart Failure"],"prefix":"10.1002","volume":"20","author":[{"given":"Jo E.","family":"Rodgers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Herbert","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality of the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators.","year":"1992","journal-title":"N Engl J Med"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(99)91340-4"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.3.564"},{"key":"e_1_2_1_8_2","first-page":"1115","article-title":"GISSI\u20103: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6\u2010week mortality and ventricular function after acute myocardial infarction","volume":"343","author":"Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico.","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"issue":"1","key":"e_1_2_1_10_2","first-page":"1","article-title":"Assessment of treatment with lisinopril and survival (ATLAS)","volume":"32","author":"Packer M.","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17388"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-3-234"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603001106"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199302000-00015"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90680-7"},{"key":"e_1_2_1_16_2","first-page":"13S","article-title":"Heterogenity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications","volume":"11","author":"Dzau VJ","year":"1993","journal-title":"J Hypertens"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(95)00349-5"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.84.8.876"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/mend.13.7.0303"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.4.1602"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.3.691"},{"issue":"1","key":"e_1_2_1_22_2","first-page":"81","article-title":"Candesartan cilexetil improves exercise tolerance and symptoms in patients with congestive heart failure [abstr]","volume":"98","author":"Riegger GAJ","year":"1998","journal-title":"Circulation"},{"key":"e_1_2_1_23_2","first-page":"133","article-title":"A randomized trial evaluating tolerability of candesartan cilexetil for patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors [abstr]","volume":"19","author":"Granger C.","year":"1998","journal-title":"Eur Heart J"},{"key":"e_1_2_1_24_2","first-page":"205A","article-title":"Effects of losartan on exercise capacity, morbidity, and mortality in patients with symptomatic heart failure [abstr]","volume":"29","author":"Klinger G.","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_25_2","first-page":"133","article-title":"Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study [abstr]","volume":"19","author":"McKelvie RS","year":"1998","journal-title":"Eur Heart J"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)84523-8"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)84525-1"},{"key":"e_1_2_1_28_2","first-page":"167","article-title":"Angiotensin II\u2010mediated cardiac hypertrophy in adult rats [abstr]","volume":"15","author":"Baker KM","year":"1991","journal-title":"J Cell Biochem"},{"key":"e_1_2_1_29_2","first-page":"A1261","article-title":"Effects of the AT1 receptor antagonist losartan on angiotensin II induced hypertrophy of rat cardiomyocytes [abstr]","volume":"6","author":"Murphy DD","year":"1992","journal-title":"FASEB J"},{"issue":"5","key":"e_1_2_1_30_2","first-page":"S37","article-title":"Effect of angiotensin II blockade on cardiac hypertrophy and remodeling: a review","volume":"9","author":"Dalhof B.","year":"1995","journal-title":"J Hum Hypertens"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2000.105302"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01187-2"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02213-3"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)84524-X"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.10.1056"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(00)90037-1"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(99)90013-1"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(99)90038-6"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00898-4"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2000.102904"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.24.5.571"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.6.1849"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1099"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119249"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)77712-6"},{"key":"e_1_2_1_47_2","first-page":"448","article-title":"Pharmacodynamic effects of dual neutral endopeptidase\u2010angiotensin\u2010converting enzyme inhibition versus angiotensin\u2010converting enzyme inhibition in humans","volume":"65","author":"Massien C.","year":"1999","journal-title":"Clin Pharmacol"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00404-4"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1999.276.5.H1769"},{"key":"e_1_2_1_50_2","first-page":"S64","article-title":"The safety and 24\u2010hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: a pilot study [abstr]","volume":"17","author":"Ruddy M.","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)80441-5"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199812000-00006"},{"key":"e_1_2_1_53_2","first-page":"185A","article-title":"Long\u2010term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure [abstr]","volume":"100","author":"Ikram H.","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_54_2","first-page":"185A","article-title":"Cardiac, renal and endocrine effects of three month treatment of chronic heart failure with the vasopeptidase inhibitor, omapatrilat [abstr]","volume":"100","author":"McClean D.","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02602-7"},{"key":"e_1_2_1_56_2","first-page":"240A","article-title":"Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: evidence from the omapatrilat heart failure program [abstr]","volume":"35","author":"Kostis JB","year":"2000","journal-title":"J Am Coll Cardiol"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.20.18.368S.34606","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.20.18.368S.34606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:19:02Z","timestamp":1761059942000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.20.18.368S.34606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":55,"journal-issue":{"issue":"11P2","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["10.1592\/phco.20.18.368S.34606"],"URL":"https:\/\/doi.org\/10.1592\/phco.20.18.368s.34606","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}